These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 18989660)

  • 1. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting.
    Benedetti F; Colombo C; Pirovano A; Marino E; Smeraldi E
    Psychopharmacology (Berl); 2009 Mar; 203(1):155-60. PubMed ID: 18989660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine.
    Benedetti F; Dallaspezia S; Colombo C; Lorenzi C; Pirovano A; Smeraldi E
    Eur Psychiatry; 2010 Dec; 25(8):476-8. PubMed ID: 20619611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin.
    Arias B; Serretti A; Lorenzi C; Gastó C; Catalán R; Fañanás L
    J Affect Disord; 2006 Feb; 90(2-3):251-6. PubMed ID: 16356553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression.
    Szegedi A; Rujescu D; Tadic A; Müller MJ; Kohnen R; Stassen HH; Dahmen N
    Pharmacogenomics J; 2005; 5(1):49-53. PubMed ID: 15520843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings.
    Taranu A; Asmar KE; Colle R; Ferreri F; Polosan M; David D; Becquemont L; Corruble E; Verstuyft C
    Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):435-441. PubMed ID: 28627776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute antidepressant response to sleep deprivation combined with light therapy is influenced by the catechol-O-methyltransferase Val(108/158)Met polymorphism.
    Benedetti F; Barbini B; Bernasconi A; Fulgosi MC; Dallaspezia S; Gavinelli C; Locatelli C; Lorenzi C; Pirovano A; Radaelli D; Smeraldi E; Colombo C
    J Affect Disord; 2010 Feb; 121(1-2):68-72. PubMed ID: 19520435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression.
    Chiesa A; Lia L; Alberti S; Lee SJ; Han C; Patkar AA; Pae CU; Serretti A
    Int J Psychiatry Clin Pract; 2014 Jun; 18(2):97-102. PubMed ID: 24555772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
    Murphy GM; Hollander SB; Rodrigues HE; Kremer C; Schatzberg AF
    Arch Gen Psychiatry; 2004 Nov; 61(11):1163-9. PubMed ID: 15520364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran.
    Yoshida K; Higuchi H; Takahashi H; Kamata M; Sato K; Inoue K; Suzuki T; Itoh K; Ozaki N
    Hum Psychopharmacol; 2008 Mar; 23(2):121-8. PubMed ID: 18023073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of mirtazapine as add-on to paroxetine
    Xiao L; Zhu X; Gillespie A; Feng Y; Zhou J; Chen X; Gao Y; Wang X; Ma X; Gao C; Xie Y; Pan X; Bai Y; Xu X; Wang G; Chen R
    Psychol Med; 2021 May; 51(7):1166-1174. PubMed ID: 31931894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder.
    Hopkins SC; Reasner DS; Koblan KS
    Psychiatry Res; 2013 Aug; 208(3):285-7. PubMed ID: 23706899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of bipolar mania is associated with catechol-O-methyltransferase Val(108/158)Met polymorphism.
    Benedetti F; Dallaspezia S; Locatelli C; Radaelli D; Poletti S; Lorenzi C; Pirovano A; Colombo C; Smeraldi E
    J Affect Disord; 2011 Jul; 132(1-2):293-6. PubMed ID: 21397335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triiodothyronine addition to paroxetine in the treatment of major depressive disorder.
    Appelhof BC; Brouwer JP; van Dyck R; Fliers E; Hoogendijk WJ; Huyser J; Schene AH; Tijssen JG; Wiersinga WM
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6271-6. PubMed ID: 15579788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.
    Kocabas NA; Faghel C; Barreto M; Kasper S; Linotte S; Mendlewicz J; Noro M; Oswald P; Souery D; Zohar J; Massat I
    Int Clin Psychopharmacol; 2010 Jul; 25(4):218-27. PubMed ID: 20531207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catechol-O-methyltransferase Val(108/158)Met polymorphism affects fronto-limbic connectivity during emotional processing in bipolar disorder.
    Vai B; Riberto M; Poletti S; Bollettini I; Lorenzi C; Colombo C; Benedetti F
    Eur Psychiatry; 2017 Mar; 41():53-59. PubMed ID: 28049082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sexual function during bupropion or paroxetine treatment of major depressive disorder.
    Kennedy SH; Fulton KA; Bagby RM; Greene AL; Cohen NL; Rafi-Tari S
    Can J Psychiatry; 2006 Mar; 51(4):234-42. PubMed ID: 16629348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients.
    Tsai SJ; Gau YT; Hong CJ; Liou YJ; Yu YW; Chen TJ
    J Affect Disord; 2009 Feb; 113(1-2):183-7. PubMed ID: 18533273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do venlafaxine XR and paroxetine equally influence negative and positive affect?
    Dichter GS; Tomarken AJ; Freid CM; Addington S; Shelton RC
    J Affect Disord; 2005 Apr; 85(3):333-9. PubMed ID: 15780704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity.
    Cusin C; Serretti A; Zanardi R; Lattuada E; Rossini D; Lilli R; Lorenzi C; Smeraldi E
    Int J Neuropsychopharmacol; 2002 Mar; 5(1):27-35. PubMed ID: 12057029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder.
    Ruhé HG; Ooteman W; Booij J; Michel MC; Moeton M; Baas F; Schene AH
    Pharmacogenet Genomics; 2009 Jan; 19(1):67-76. PubMed ID: 18987562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.